E-ISSN: 1305-3612
    Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST
    PDF
    Cite
    Share
    Request
    Interventional Radiology - Original Article
    VOLUME: 27 ISSUE: 1
    P: 85-93
    January 2021

    Transarterial chemoembolization with drug-eluting beads in patients with hepatocellular carcinoma: response analysis with mRECIST

    Diagn Interv Radiol 2021;27(1):85-93
    DOI: 10.5152/dir.2020.19439
    Claudia Domaratius 1
    Utz Settmacher 2
    Christina Malessa 2
    Ulf Teichgräber 1
    1. Department of Radiology, University Hospital Jena, Friedrich Schiller University, Jena, Germany
    2. Department of General, Visceral and Vascular Surgery, University Hospital Jena, Friedrich Schiller University, Jena, Germany
    No information available.
    No information available
    Received Date: 12.09.2019
    Accepted Date: 10.07.2020
    PDF
    Cite
    Share
    Request

    ABSTRACT

    PURPOSE

    According to the Barcelona Clinic Liver Cancer (BCLC) staging classification, transarterial chemoembolization (TACE) is the treatment of choice for intermediate hepatocellular carcinoma (HCC). Thereby, the use of drug-eluting beads (DEB) as embolic agents has been recently established in clinical practice. The aim of this study was to evaluate tumor response after DEB-TACE.

    METHODS

    This retrospective study was approved by the institutional ethics committee. Overall, 89 patients with HCC (Child Pugh A or B) receiving DEB-TACE as palliative treatment option or as bridging before liver transplantation were included in the study. Tumor response was assessed by modified response evaluation criteria in solid tumors (mRECIST) and a tumor growth rate. Survival analysis was performed using Kaplan-Meier estimator with log-rank testing and Cox proportional hazards.

    RESULTS

    A total of 188 TACE procedures were performed between 2006 and 2010. After the last intervention, 18% achieved complete response, 45% achieved partial response, 28% had stable disease and 9% had progressive disease. Using the tumor growth rate, 90% of all patients showed a tumor reduction between first and final response evaluation. The 6-month, 1-, 2- and 3-year overall survival rates were 86.5%, 67.4%, 47.2%, and 33.7%, with a median survival of 45, 24, 15, and 14 months for complete response, partial response, stable disease, and progressive disease, respectively. Tumor reduction showed a positive effect on survival.

    CONCLUSION

    DEB-TACE offers conclusive response results with mRECIST and proves a strong tendency of tumor reduction on survival benefits. Therefore, tumor growth rate represents a possible parameter to predict survival.

    Keywords:

    2024 ©️ Galenos Publishing House